Full Study Name

GENPROS - Analysing outcomes after prostate cancer diagnosis and treatment in carriers of rare germline mutations in cancer predisposition genes

Local Principal Investigator

Prof Ros Eeles

Study Status


Main Aims
  • To investigate whether PCa patients who carry a rare germline mutation have shorter CSS compared to non-carriers
  • To investigate whether PCa patients with rare germline mutations have a shorter biochemical progression free survival (bPFS) and metastasis free survival (MFS) after radical treatment for PCa than non-carriers. The study will also analyse progression free survival (PFS) and CSS from metastasis (CSS_M1).
  • To perform genetic profiling to investigate whether common allele profiles or specific common alleles also have an association with prognosis and treatment outcome.
Inclusion Criteria
  • Men diagnosed with prostate cancer
  • Known carriers of germline mutations associated with PCa risk
  • Known non-carriers of mutations in the genes above
Exclusion Criteria
  • Patients under 18 years of age
  • Patients who are unable to give informed consent
  • Patients who cannot be traced (<6 months follow-up) or whose clinical data are not available
  • Patients whose genetic status is unknown
  • Patients who have been diagnosed with prostate cancer through the IMPACT study
Open Sites

Royal Marsden, Glasgow, Aberdeen, Exeter, Leeds, Edinburgh, Oxford, Birmingham, Dundee, GOSH, Bristol, Guy's, St George's, Cardiff, Belfast, Nottingham, Southampton, Liverpool, Sheffield, Cambridge, North West London, Manchester, Newcastle

For more information click here